Association of Computed Tomography Radiomics Signature with Progression-free Survival in Neuroblastoma Patients

被引:2
|
作者
Wang, H. [1 ]
Li, T. [1 ]
Xie, M. [1 ]
Si, J. [1 ]
Qin, J. [1 ]
Yang, Y. [1 ]
Zhang, L. [1 ]
Ding, H. [1 ]
Chen, X. [1 ]
He, L. [1 ]
机构
[1] Chongqing Med Univ, Natl Clin Res Ctr Child Hlth & Disorders, Childrens Hosp,Key Lab Child Dev & Disorders, Minist Educ,Chongqing Key Lab Pediat,Dept Neurol, 136 Zhongshan Rd 2, Chongqing 400014, Peoples R China
关键词
Computed tomography; neuroblastoma; prognosis; progression-free survival; radiomics; PATHOLOGY CLASSIFICATION; PROGNOSTIC VALUE;
D O I
10.1016/j.clon.2023.06.008
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aims: To investigate the association of computed tomography radiomics signature with progression-free survival (PFS) in neuroblastoma patients. Materials and methods: We retrospectively included 167 neuroblastoma patients who were divided into a training set and a test set through stratified sampling at a ratio of 7:3. Regions of interest of the primary tumours were delineated on pretreatment contrast-enhanced computed tomography images and radiomics features were extracted from them. The intraclass correlation coefficient, Pearson correlation coefficient, and least absolute shrinkage and selection operator Cox regression algorithm were applied to select radiomics features and construct the radiomics signature. The effectiveness of the signature in predicting PFS was evaluated using the concordance index (C-index) and 95% confidence interval in both the training and the test sets. The time-dependent receiver operator characteristic curve of the radiomics signature was plotted and the area under the curve (AUC) was calculated. A calibration curve was used to assess the difference between the predicted probability of the radiomics signature and the observed probability at different time points. Results: The radiomics signature was composed of six features, which achieved a C-index of 0.733 (95% confidence interval 0.664-0.803) in the training set and 0.734 (95% confidence interval 0.608-0.861) in the test set. In the training set, the radiomics signature yielded an AUC of 0.707, 0.737, 0.788, 0.859 and 0.829 for 1-, 2-, 3-, 4- and 5-year PFS, respectively. Similarly, the radiomics signature exhibited an AUC of 0.738, 0.807, 0.761, 0.787 and 0.818 for 1-, 2-, 3-, 4- and 5-year PFS, respectively, in the test set. The calibration curves showed no significant difference between the predicted probability of the radiomics signature and the observed probability for up to 5 years. Conclusions: Computed tomography radiomics features exhibit a significant correlation with the PFS of neuroblastoma patients, particularly in terms of longterm outcomes. (c) 2023 Published by Elsevier Ltd on behalf of The Royal College of Radiologists.
引用
收藏
页码:e639 / e647
页数:9
相关论文
共 50 条
  • [31] An Audit Strategy for Progression-Free Survival
    Dodd, Lori E.
    Korn, Edward L.
    Freidlin, Boris
    Gray, Robert
    Bhattacharya, Suman
    BIOMETRICS, 2011, 67 (03) : 1092 - 1099
  • [32] QUANTITATIVE ESTIMATION OF PROGRESSION-FREE SURVIVAL BASED ON RADIOMICS ANALYSIS OF PREOPERATIVE MULTI-PARAMETRIC MRI IN PATIENTS WITH GLIOBLASTOMA
    Kazerooni, Anahita Fathi
    Rathore, Saima
    Akbari, Hamed
    Rudie, Jeffrey
    Sako, Chiharu
    Ha, Sung Min
    Mamourian, Elizabeth
    Bakas, Spyridon
    Shukla, Gaurav
    Bilello, Michel
    Davatzikos, Christos
    NEURO-ONCOLOGY, 2019, 21 : 168 - 169
  • [33] Development and validation of a preoperative MRI-based radiomics nomogram to predict progression-free survival in patients with clival chordomas
    Zhai, Yixuan
    Bai, Jiwei
    Xue, Yake
    Li, Mingxuan
    Mao, Wenbin
    Zhang, Xuezhi
    Zhang, Yazhuo
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [34] Bevacizumab 'prolongs progression-free survival'
    Saul, Helen
    EUROPEAN JOURNAL OF CANCER, 2010, 46 (12) : 2136 - 2136
  • [35] Oxaliplatin improves progression-free survival in patients with colorectal cancer
    不详
    ONCOLOGY-NEW YORK, 2001, 15 (01): : 83 - 83
  • [37] The Impact of Staging by Positron-Emission Tomography on Overall Survival and Progression-Free Survival in Patients With Locally Advanced NSCLC
    Vokes, Everett E.
    Govindan, Ramaswamy
    Iscoe, Neill
    Hossain, Anwar M.
    San Antonio, Belen
    Chouaki, Nadia
    Koczywas, Marianna
    Senan, Suresh
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (08) : 1183 - 1188
  • [38] A radiomic signature as a non-invasive predictor of progression-free survival in patients with lower-grade gliomas
    Liu, Xing
    Li, Yiming
    Qian, Zenghui
    Sun, Zhiyan
    Xu, Kaibin
    Wang, Kai
    Liu, Shuai
    Fan, Xing
    Li, Shaowu
    Zhang, Zhong
    Jiang, Tao
    Wang, Yinyan
    NEUROIMAGE-CLINICAL, 2018, 20 : 1070 - 1077
  • [39] A RADIOMIC SIGNATURE AS A NON-INVASIVE PREDICTOR OF PROGRESSION-FREE SURVIVAL IN PATIENTS WITH LOWER-GRADE GLIOMAS
    Wang, Yinyan
    Liu, Xing
    Li, Yiming
    Sun, Zhiyan
    NEURO-ONCOLOGY, 2018, 20 : 193 - 194
  • [40] A Nomogram for Predicting Progression-free Survival in Patients with Endometrial Cancer
    Wang, Z.
    Zhao, Z.
    Li, W.
    Bao, X.
    Liu, T.
    Yang, X.
    CLINICAL ONCOLOGY, 2023, 35 (09) : e516 - e527